EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study

Samantha B Shapiro iD, Hui Yin, Oriana Hoi Yun Yu iD, Soham Rej iD, Samy Suissa iD, Laurent Azoulay iD

BMJ · 26.02.2025 · 388 · e080679

DOI: 10.1136/bmj-2024-080679 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift BMJ, online erschienen am 26.02.2025. Verfasst von Samantha B Shapiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Design

Active comparator, new user cohort study.

Setting

Primary care practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics Admitted Patient Care and Office for National Statistics Death Registration databases.

Participants

Patients with type 2 diabetes. Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020. Both cohorts were followed until 29 March 2021. Main outcome measures The primary outcome was suicidality, defined as a composite of suicidal ideation, self-harm, and suicide. Secondary outcomes were each of these events considered separately. Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios and 95% confidence intervals (CIs) to estimate the average treatment effect among the treated patients.

Results

The first cohort included 36 082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234 028 DPP-4 inhibitor users (median follow-up 1.7 years). In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively; hazard ratio 2.08, 95% CI 1.83 to 2.36). This estimate decreased to a null value after confounding factors were accounted for (hazard ratio 1.02, 95% CI 0.85 to 1.23). The second cohort included 32 336 GLP-1 receptor agonist users (median follow-up 1.2 years) and 96 212 SGLT-2 inhibitor users (median follow-up 1.2 years). Similarly, GLP-1 receptor agonist use was associated with an increased risk of suicidality compared with SGLT-2 inhibitors in crude analyses (crude incidence rates 4.3 v 2.7 per 1000 person years; hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12). Similar findings were observed when suicidal ideation, self-harm, and suicide were analysed separately in both cohorts.

Conclusions

In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSuicidal IdeationSuicideHumansMaleFemaleMiddle AgedAgedUnited KingdomSodium-Glucose Transporter 2 InhibitorsCohort StudiesSelf-Injurious BehaviorRisk Factors

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.
  • Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
  • Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada.
  • Division of Endocrinology & Metabolism, McGill University, Montreal, QC, Canada.
  • Department of Psychiatry, Jewish General Hospital, Montreal, QC, Canada.
  • Department of Psychiatry, McGill University, Montreal, QC, Canada.

ORCID-Profile: Samantha B Shapiro, Oriana Hoi Yun Yu, Soham Rej, Samy Suissa, Laurent Azoulay

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025). Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ, 388, e080679. https://doi.org/10.1136/bmj-2024-080679

Vancouver

Shapiro SB, Yin H, Yu OHY, Rej S, Suissa S, Azoulay L. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. 2025;388:e080679. doi:10.1136/bmj-2024-080679

BibTeX
@article{Shapiro2025,
  author = {Shapiro, Samantha B and Yin, Hui and Yu, Oriana Hoi Yun and Rej, Soham and Suissa, Samy and Azoulay, Laurent},
  title = {Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study},
  journal = {BMJ},
  year = {2025},
  volume = {388},
  pages = {e080679},
  doi = {10.1136/bmj-2024-080679}
}
Kostenlos starten →